Floatz logo

Docetaxel

Chronic Lymphocytic Leukemia

IGM Biosciences, Inc.Small moleculePhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
65/ 100

Competitive context

144 Active assets in the Chronic Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
CHLORAMBUCIL
Ascentage Pharma Group Inc.
Phase 4BBB
Zofran
Dizal Pharmaceuticals
Phase 4BB
Venetoclax
City of Hope Medical Center
Phase 4BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
M.D. Anderson Cancer Center
Phase 4BB

View all 50 →

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
pancreatic adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →